Dr. Mark Levitan, MD

Dr. Levitan practices at Austin Retina Associates in Austin, Texas.

Dr. Levitan's NPI, 1609848399, was assigned on February 6, 2006. Dr. Levitan graduated from SUNY Downstate Health Sciences University in 1985. Dr. Levitan holds Texas license J3839.

Dr. Levitan's primary practice is Austin Retina Associates, at 1512 W 35th St, Austin, TX 78703 in Travis County. The practice phone is (512) 451-0103.

Dr. Levitan's primary practice is Austin Retina Associates in Austin, Texas. Dmand AI also links Dr. Levitan to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Levitan practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Levitan's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Levitan is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Levitan's licenses on file in 6 states: Texas, New York, Florida, New Jersey, Pennsylvania and Georgia.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, inflammation of iris, retinal detachment, retinal occlusion and surgical retina and vitreous procedures among the conditions Dr. Levitan treats.

CMS data shows 21,292 Medicare services from Dr. Levitan across 19 procedure codes in 2024, for 945 Medicare patients. Medicare paid $2,967,079 for them. Every service was in an office.

CMS counts 945 Medicare patients who saw Dr. Levitan in 2024. The largest group is 75 to 84, with 388 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Levitan's median patient age at 75, with 58% women.

In 2024, Dr. Levitan wrote 83 Medicare Part D claims for 44 patients. 76% of them were for generic drugs. CMS names the drug for 25 of them, across 1 drug with 11 or more claims each, at $960 in total drug cost. In 2023, CMS named 29 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Levitan for performance year 2024, reported individually. Dr. Levitan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 2 papers to Dr. Levitan. Dr. Levitan's most frequent co-authors are James W. Dooner, MD, Clio Armitage Harper, MD and Peter A. Nixon, MD.

CMS Open Payments shows 85 general payments to Dr. Levitan from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Baxter Healthcare paid the most, $32,472.

Dr. Levitan graduated from SUNY Downstate Health Sciences University in 1985.

Dr. Levitan is in network with 21 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.